• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    IDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/1/25 6:30:23 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $IDXX alert in real time by email
    false IDEXX LABORATORIES INC /DE 0000874716 0000874716 2025-05-01 2025-05-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K  

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): May 1, 2025

     

    IDEXX LABORATORIES, INC.

    (Exact name of registrant as specified in its charter)

      

    Delaware   000-19271   01-0393723
    (State or other jurisdiction   (Commission File Number)   (IRS Employer Identification No.)
    of incorporation)        

     

    One IDEXX Drive, Westbrook, Maine       04092

    (Address of principal executive offices)

          (ZIP Code)

     

    207.556.0300

    (Registrant's telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

      ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.10 par value per share   IDXX   NASDAQ Global Select Market

      

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition.

     

    On May 1, 2025, IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    In accordance with general instructions to Form 8-K, the information in this Form 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

     

    Item 9.01Financial Statements and Exhibits.

     

    (d)      Exhibits

     

        The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.

     

    Exhibit No. Description of Exhibit

     

    99.1

    Press Release entitled “IDEXX Laboratories Announces First Quarter Results,” issued by the Company on May 1, 2025.

     

    104Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        IDEXX LABORATORIES, INC.
       
    Date: May 1, 2025 By: /s/ Andrew Emerson 
        Andrew Emerson
        Executive Vice President,
    Chief Financial Officer and Treasurer

     

    2 

     

    Get the next $IDXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IDXX

    DatePrice TargetRatingAnalyst
    12/2/2024$500.00Outperform
    Leerink Partners
    7/25/2024$580.00Buy
    BTIG Research
    1/30/2024$525.00Overweight → Neutral
    Piper Sandler
    12/7/2023$602.00Outperform
    Exane BNP Paribas
    12/4/2023Neutral → Buy
    Cleveland Research
    8/2/2023$610.00Overweight → Neutral
    Atlantic Equities
    7/25/2022$415.00Buy → Hold
    Stifel
    7/21/2022$530.00 → $435.00Neutral → Buy
    Goldman
    More analyst ratings

    $IDXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Vice President Johnson Michael Perkins covered exercise/tax liability with 1,499 shares and converted options into 3,382 shares, increasing direct ownership by 390% to 2,365 units (SEC Form 4)

      4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      6/3/25 5:00:38 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Szostak M Anne exercised 1,046 shares at a strike of $160.28 and sold $1,182,917 worth of shares (2,306 units at $512.97) (SEC Form 4)

      4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      5/23/25 5:00:20 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Junius Daniel M exercised 2,683 shares at a strike of $263.81 and sold $1,358,697 worth of shares (2,683 units at $506.41) (SEC Form 4)

      4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      5/14/25 5:00:15 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IDEXX Laboratories to Release 2025 Second Quarter Financial Results

      IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 second quarter financial results for Monday, August 4, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen

      6/24/25 1:00:00 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders

      The Catalyst® Cortisol Test provides veterinarians with real-time critical insights when evaluating dogs for Addison's disease and Cushing's syndrome WESTBROOK, Maine, June 5, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst® Cortisol Test, which measures real-time quantitative cortisol concentrations to support the diagnosis of Addison's disease and diagnosis and management of Cushing's syndrome in dogs. IDEXX's Catalyst Cortisol Test is the third menu expansion in under a year for the Catalyst platform, further advancing the diagnostic capabilities available to veterinary practices at the p

      6/5/25 7:00:00 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day

      IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT). A live audio webcast of the presentation will be available through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the presentation will be available via the same link. 2025 Investor Day IDEXX Laboratories, Inc. also announced today that it will host its 2025 Investor Day on Thursday,

      5/13/25 2:30:00 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on IDEXX Labs with a new price target

      Leerink Partners initiated coverage of IDEXX Labs with a rating of Outperform and set a new price target of $500.00

      12/2/24 6:57:33 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • BTIG Research initiated coverage on IDEXX Labs with a new price target

      BTIG Research initiated coverage of IDEXX Labs with a rating of Buy and set a new price target of $580.00

      7/25/24 6:47:32 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Labs downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded IDEXX Labs from Overweight to Neutral and set a new price target of $525.00

      1/30/24 6:59:50 AM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $IDXX
    SEC Filings

    See more
    • SEC Form SD filed by IDEXX Laboratories Inc.

      SD - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

      5/30/25 4:02:56 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • IDEXX Laboratories Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

      5/9/25 4:00:15 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by IDEXX Laboratories Inc.

      10-Q - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

      5/1/25 4:11:17 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care